Eli Lilly inks $200M armed antibody pact with ImmunoGen

ImmunoGen ($IMGN) says it's struck a $200 million deal to collaborate with Eli Lilly ($LLY) on developing new armed antibodies. In a filing with the SEC the biotech adds that Lilly will also pay out unspecified royalties on any approved drugs to come out of the pact, which deals with a specific antigen. The company's claim to fame so far rests with the pioneering anticancer technology behind Roche's ($RHHBY) Kadcyla. Filing